Original research

Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis

Boun Kim Tan,1 Sabine Mainbourg,2,3 Arnaud Friggeri,1 Laurent Bertoletti4,5 Marion Douplat,6 Yesim Dargaud,7,8 Claire Grange,2 Hervé Lobbes4,9 Steeve Provencher,10 Jean-Christophe Lega2,3,7

ABSTRACT

Background The prevalence of venous thromboembolic event (VTE) and arterial thromboembolic event (ATE) thromboembolic events in patients with COVID-19 remains largely unknown.

Methods In this meta-analysis, we systematically searched for observational studies describing the prevalence of VTE and ATE in COVID-19 up to 30 September 2020. 

Results We analysed findings from 102 studies (64,503 patients). The frequency of COVID-19-related VTE was 14.7% (95% CI 12.1% to 17.6%, I²=94%; 56 studies; 16,507 patients). The overall prevalence rates of pulmonary embolism (PE) and leg deep vein thrombosis were 7.8% (95% CI 6.2% to 9.4%, I²=94%; 66 studies; 23,117 patients) and 11.2% (95% CI 8.4% to 14.3%, I²=95%; 48 studies; 13,824 patients), respectively. Few were isolated subsegmental PE. The VTE prevalence was significantly higher in intensive care unit (ICU) (23.2%, 95% CI 17.5% to 29.6%, I²=92%; vs 9.0%, 95% CI 6.9% to 11.4%, I²=95%; pinteraction<0.0001) and in series systematically screening patients compared with series testing symptomatic patients (25.2% vs 12.7%, pinteraction=0.04). The frequency rates of overall ATE, acute coronary syndrome, stroke and other ATE were 3.9% (95% CI 2.0% to 3.0%, I²=96%; 16 studies; 7,939 patients), 1.6% (95% CI 1.0% to 2.2%, I²=93%; 27 studies; 40,597 patients) and 0.9% (95% CI 0.5% to 1.5%, I²=84%; 17 studies; 20,139 patients), respectively. Metaregression and subgroup analyses failed to explain heterogeneity of overall ATE. High heterogeneity limited the value of estimates.

Conclusions Patients admitted in the ICU for severe COVID-19 had a high risk of VTE. Conversely, further studies are needed to determine the specific effects of COVID-19 on the risk of ATE or VTE in less severe forms of the disease.

INTRODUCTION

COVID-19 is a viral respiratory illness caused by SARS-CoV-2. In severe cases, COVID-19 is characterised by cytokine outburst and hyperinflammation, platelet activation, endothelial dysfunction and sepsis-related coagulopathy.1 Consistently, high levels of D-dimers were repeatedly shown to be associated with the need for intensive care unit (ICU) admission and mortality among patients with COVID-19.2 While initial anecdotal reports described cases of pulmonary embolism (PE) diagnosed concomitantly with COVID-19,3 more recent observational studies suggested that venous thromboembolic events (VTEs) are common among patients with COVID-19 hospitalised in the ICU, thrombosis prevalence ranging from 0%6 to 69%.7 Few series also suggested an elevated incidence of arterial thromboembolic events (ATEs).6 7 Importantly, however, these prevalence estimates have been largely inconsistent with a high heterogeneity across studies and are subjected to several biases. Moreover, many series also reported a low prevalence of deep vein thrombosis (DVT),4 questioning the peculiar mechanism responsible for pulmonary vessel occlusions.

While international experts recently recommended an early therapeutic anticoagulation for these patients despite the increased risk of bleeding and previous negative trials of endogenous anticoagulants in sepsis,4,8 relevant estimates of the occurrence of ATE and VTE are lacking to inform on the best therapeutic approach in these patients. Therefore, the present meta-analysis aimed to determine the prevalence of VTE and ATE in patients with COVID-19.

MATERIALS AND METHODS This systematic review and meta-analysis (http://www.crdd.york.ac.uk/PROSPERO, CRD42020184252) was conducted in accordance with the Cochrane Handbook for Systematic Reviews

Key messages

What is the key question?

Are arterial and venous thromboembolic events common in patients with COVID-19, and what condition may modify their prevalence?

What is the bottom line?

Our results suggested that venous and, to a lesser extent, arterial thromboembolism, are common in patients with COVID-19 admitted in the intensive care unit, despite thromboprophylaxis. The systematic screening of venous thromboembolism may be relevant.

Why read on?

This is the first systematic evaluation of existing evidence regarding thrombotic manifestations of COVID-19, summarising the current evidence on a novel spectrum of this viral disease.
of Interventions\textsuperscript{10} and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.\textsuperscript{11}

Search strategy
A literature search was performed to identify all published studies reporting thromboembolic events in COVID-19. MEDLINE, Embase and Google Scholar were searched between 1 January 2020 and 30 September 2020 using the keywords “coronavirus”, “severe acute respiratory syndrome coronavirus 2”, “SARS-CoV-2”, “novel coronavirus”, “nCoV”, “2019-nCoV”, and “COVID-19” and “thrombosis”, “stroke”, “myocardial infarction”, “acute coronary syndrome”, “pulmonary embolism” and “venous thromboembolism” (see appendix). The websites of major journals were also searched, including the New England Journal of Medicine, Journal of the American Medical Association, Lancet, Lancet Haematology, British Medical Journal, Journal of the American College of Cardiology, Circulation, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis and Thrombosis Research. Bibliographies of each included study, as well as any review article, systematic review, meta-analysis or text found were also searched for additional papers that may contain further studies. Given that preprint papers in databases such as bioRxiv and medRxiv were not peer-reviewed, we did not include papers found in such databases in our analysis to avoid any potential misinformation being disseminated. There was no restriction on the language and type of publication.

Study selection
The inclusion criteria for studies were the following: (1) cohort studies of >10 patients, (2) patients with COVID-19 (positive reverse transcription PCR (RT-PCR)) or positive CT scan in patients with suggestive gestalt) and (3) available rate of objectively documented ATE or VTE as defined by investigators. Moreover, publications specific to the paediatric population were excluded. The titles and abstracts of all articles were independently reviewed by two authors (BKT and J-CL). If pertinent, each reviewer independently retrieved and explored complete articles to make a final decision about their inclusion in the meta-analysis. Disagreements were resolved by consensus or by consulting a third reviewer (SM). Throughout this process, the reviewers were blinded to authors’ names, journal and year of publication of the papers. If studies that had been reported in multiple papers were identified, the analysis was limited to the largest cohort unless the necessary data had appeared only in another paper. A log of reasons for rejection of citations identified from the searches was kept.

Outcomes
The main outcomes were the rate of distal (located below the knee) and proximal (involving popliteal, femoral, iliac vein and inferior vena cava) DVT, VTE (distal and proximal DVT and PE) and the rate of ATE (myocardial infarction, stroke, limb and visceral arterial ischaemia).

Assessment of methodological quality
The methodological quality of the selected studies was systemat-ically evaluated using the Methodological Index for Non-randomised Studies (MINORS), which contains six items for non-comparative studies.\textsuperscript{12}

Data extraction
Two reviewers (BKT and J-CL) independently extracted study design; the study country; patient characteristics, including the proportion of patients hospitalised in the ICU; the method used to diagnose COVID-19 and VTE; the follow-up duration, whether symptomatic testing versus asymptomatic screening was performed; and the proportion of patients receiving anticoagulants.

Statistical analysis
We constructed a random-effects (Mantel-Haenszel) model to obtain a summary estimate and 95% CI for the prevalence of VTE and ATE using arcane transformation. These data were combined using an approach to the inverse variance approach, effectively weighting each study according to its sample size. Arcsine transformation was used to stabilise the variance.\textsuperscript{13} F statistic for heterogeneity was used to assess between study heterogeneity. To investigate sources of heterogeneity in the main analysis, if any, we planned a priori subgroup analyses for relevant categorical variables (single centre vs multicentre, consecutive vs non-consecutive series, retrospective vs prospective, systematic assessment of thrombosis vs symptomatic testing, a majority of included patients being hospitalised within the ICU or not), as well as metaregression for continuous variables (study size, the MINORS score, proportion of male sex,\textsuperscript{14} mean lymphocyte count\textsuperscript{15} and D-dimer value,\textsuperscript{15} proportion of patients hospitalised in the ICU,\textsuperscript{14} proportion of patients receiving anticoagulants). Metaregression was not performed if the number of studies was ≤10 to avoid overfitting using linear weighted random/mixed-effects model (rma function, metafor package).\textsuperscript{16}

Publication bias was assessed visually using funnel plots. We assumed that the effect of publication bias should be minor if the plot of the magnitude of effect size in each study versus its precision estimate (ie, SE) shows a roughly symmetrical funnel shape. We also formally tested the presence of publication bias using the SE-based and study size-based funnel plot and related asymmetry tests. All analyses were performed with R (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Literature search and agreement
A total of 2554 articles were retrieved by the search terms. After reviewing titles and abstracts, 165 articles were selected for the full-text eligibility. Finally, 102 studies (64 503 patients) were included (figure 1).

Study characteristics
Among included studies, 81 series assessed COVID-19-related VTE and 20 studies reported ATE. The characteristics of the included studies are described in online supplemental table S1. The patient number varied from 12 to 12 630. Twenty-three (23%) studies were prospective; 74 (73%) included consecutive patients. Thirty-four (33%) studies were conducted in ICU. Two studies used electronic medical records to identify thrombotic events.\textsuperscript{17}–\textsuperscript{18} Eligible studies ranged in size from 12 to 12 630 patients, while mean follow-up duration ranged from 8 to 86 days. The presence of DVT and PE was confirmed with ultrasonography and CT scan, respectively, although PE was confirmed by echocardiography in patients with high suspicion in two studies.\textsuperscript{17}–\textsuperscript{18} Thirty-seven (36%) studies, mainly letters, did not report the method of VTE detection. The all-cause mortality varied from 0% to 64%. The rate of patients receiving pharmacological VTE prophylaxis ranged from 16% to 100%.

Tan BK, et al. Thorax 2021;0:1–10. doi:10.1136/thoraxjnl-2020-215383
Critical care

The overall weighted frequency of COVID-19-related VTE was 14.7% (95% CI 12.1% to 17.6%, I²=94%; 56 studies; 16,507 patients; figure 2).4 5 15 17–68 The visual inspection of funnel plot and the Egger’s regression test (p<0.0001) were in favour of publication bias (online supplemental figure S1). VTE included PE (7.8%, 95% CI 6.2% to 9.4%, I²=94%; 66 studies; 23,117 patients; online supplemental figure S2)4–7 15 17 18 22–25 29–31 33 34 36–52 55 56 58 59 61 63–67 69–88 and leg DVT (11.2%, 95% CI 8.4% to 14.3%; I²=95%; 48 studies; 13,824 patients; online supplemental figure S3).4–7 15 17 19–22 25–29 31 33 34 36 37 41–43 48–51 55–58 60 61 64 65 67 69–72 75 89–98 Few PE events resulted from isolated subsegmental PE (1.5%, 95% CI 0.9% to 2.4%; I²=73%; 22 studies; 1391 patients; online supplemental figure S4),4 7 17 24 30 34 39 48 51 53 55–57 60 61 64 67 69 73 76 81 99 whereas distal DVT (10.9%, 95% CI 4.8% to 18.9%, I²=97%; 19 studies; 2421 patients; online supplemental figure S5).4–7 15 17 19–22 23 26 30 34 36 38 39 40 41 49 53 55–57 59 65 67 88–90 93 94 97 100 was more frequent than proximal DVT (4.8%, 95% CI 2.8% to 7.2%, I²=89%; 26 studies; 3735 patients; online supplemental figure S5).4–7 17 19 22 23 26 30 34 36 38 40 41 49 53 55–57 59 65 67 88–90 93 94 97 100

In subgroup analyses, the VTE prevalence was significantly higher in ICU cohorts than cohorts including mixed patients (23.2%, 95% CI 17.4% to 29.6%; I²=92%; vs 10.0%, 95% CI 6.9% to 11.4%; I²=95%; pinteraction<0.0001; figure 2 and table 1). Post hoc subgroup analyses retrieved similar interactions for PE (13.5%, 95% CI 9.5% to 18.1% vs 5.2%; 95% CI 3.9 to 6.7; pinteraction<0.0001; online supplemental figure S2), DVT (21.1%, 95% CI 13.8% to 29.5% vs 4.7%, 95% CI 2.9 to 6.8; pinteraction<0.0001; online supplemental figure S3) and proximal DVT (9.0%, 95% CI 3.5% to 16.6% vs 2.6%, 95% CI 1.2 to 4.5; pinteraction<0.0001; online supplemental figure S6). This relation between ICU admission and VTE prevalence was supported by metaregression analyses (table 2 and figure 3). In addition, the VTE prevalence was higher in multicentric versus monocentric series, in studies using systematic screening versus symptomatic testing (table 2 and online supplemental figure S7), in larger cohorts and in studies with high mean D-dimers values (table 2). Conversely, the VTE prevalence was not associated with the MINORS score, the proportion of patients receiving anticoagulation or the study design, and proportion of men (tables 2 and 3). The rate of ICU patients and systematic screening were significantly associated to VTE prevalence in multivariable metaregression (table 3).

Arterial thromboembolism

The weighted frequency of ATE was 4.0% (95% CI 2.0% to 6.5%, I²=95%; 19 studies; 8249 patients),7 17 18 27 36 39 47 50 51 53–55 61 65–67 88 101–103 including myocardial infarction/acute coronary syndrome (1.1%, 95% CI 0.2% to 3.0%, I²=96%; 16 studies; 7939 patients),7 17 18 39 47 50 51 53 55 61 65 66 88 101–103 ischaemic stroke (1.6%, 95% CI 1.0% to 2.2%, I²=93%; 27 studies; 40 597 patients)7 17 18 27 36 39 42 43 50 51 53 55 61 65–67 88 101 102 104–112 and other ATE (0.9%, 95% CI 0.5% to 1.5%; I²=84%; 17 studies; 20 139 patients)7 17 18 27 36 39 42 43 47 50 51 53 55 61–67 88 101 102 106 (figure 4).

The visual inspection of funnel plot and Egger’s regression test (p=0.008) were in favour of publication bias (online supplemental figure S1). Subgroup analyses (online supplemental table
Figure 2  Forest plot showing the pooled, weighted frequency of patients with venous thromboembolic events related to COVID-19 according to patient population. ICU, intensive care unit.
S3) and metaregression (online supplemental table S4) failed to identify other factor explained heterogeneity.

**DISCUSSION**

The present meta-analysis showed a high prevalence of VTE in patients with COVID-19, especially for those admitted to the ICU. The prevalence of ATE was also substantial, although the low number of studies reporting this outcome among patients with COVID-19 limited precise estimates of the ATE risk according to patients’ characteristics. Taken together, these observations suggest that systemic inflammation, traditional predisposing factors for VTE, as well as potential SARS-CoV2–COVID-19 endothelium interaction likely predispose to VTE and ATE in patients with severe COVID-19. Therefore, physicians should be aware of these complications and remain vigilant for signs of VTE and ATE in the context of the current pandemic.

With the number of identified COVID-19 cases increasing worldwide, it has become clear that infected patients may present in a number of ways. Early observational studies suggested that virtually all patients had parenchymal abnormalities on chest CT.113 Interestingly, however, pulmonary vascular thickening were also frequently observed in COVID-19 compared with non-COVID-19 pneumonia, implying a potential tropism of the virus for the pulmonary vasculature.114 This is not surprising since the SARS-CoV-2 interacts with its functional receptor from the host cells, the ACE 2 receptor,115 also present on the surface of endothelial cells of virtually all organs, but predominantly within the heart, lungs and kidneys.116 Consistently, diffuse lymphocytic endotheliitis, endothelial dysfunction and apoptosis resulting from direct viral infection have been reported within the lungs and other organs.117 Subsequently, observational studies suggested that VTE was common among patients with COVID-19 admitted to the ICU as well as a common autopsy finding following COVID-19-positive deaths despite systematic thrombosis prophylaxis.118

The present meta-analysis is consistent with these early descriptions. Interestingly, however, the VTE prevalence varied widely between included series. A major cause of these fluctuations was the study design: patients admitted to the ICU had a twofold increased risk of VTE compared with those admitted on general wards.14 99 Not surprisingly, asymptomatic screening was also associated with a higher VTE prevalence compared with symptomatic testing only. Other risk factors associated with VTE reported in series included increasing age,15 lymphopenia,15 34 male sex,14 34 increased D-dimer,15 34 60 99 increased

| Table 1 | Subgroup analysis to explore heterogeneity in estimate of VTE prevalence |
|---------|-------------|-----------------|-----------------|-----------------|-----------------|
|                     | Studies (k) | Patients (n) | Prevalence (%) (95% CI) | I² (%) | P value |
| Approach to VTE diagnosis | | | | | |
| Asymptomatic screening | 12 | 842 | 25.2 (13.5 to 39.1) | 95 | |
| Symptomatic testing only | 44 | 15665 | 12.7 (10.1 to 15.4) | 96 | |
| Patients in ICU | | | | | |
| >70% | 26 | 1686 | 23.2 (17.4 to 29.6) | 92 | |
| ≤70% | 30 | 14052 | 9.0 (6.9 to 11.4) | 95 | |
| Prospective series | | | | | |
| Yes | 12 | 14653 | 13.1 (10.4 to 16.1) | 96 | |
| No/unknown | 44 | 1828 | 22.0 (12.9 to 32.7) | 96 | |
| Multicentric series | | | | | |
| Yes | 12 | 2808 | 28.5 (16.2 to 42.6) | 98 | |
| No | 44 | 13673 | 14.3 (10.6 to 18.5) | 94 | |
| Consecutive series | | | | | |
| Yes | 14 | 11495 | 15.5 (12.2 to 19.2) | 96 | |
| No/unknown | 42 | 4986 | 12.7 (7.7 to 18.8) | 95 | |

ICU, intensive care unit; VTE, venous thromboembolism.

| Table 2 | Metaregression to explore heterogeneity in estimate of venous thromboembolism prevalence |
|---------|-------------|-----------------|-----------------|-----------------|-----------------|
|                     | Studies (n) | Beta (95% CI)* | Intercept† | P value | R² (%) |
| Number of patients‡ | 56 | −0.0082 (−0.0143 to −0.0021) | 0.1929 | 0.008 | 11 |
| Proportion of patients in ICU | 56 | 0.0017 (0.0008 to 0.0025) | 0.0816 | <0.0001 | 28 |
| MINORS score | 31 | 0.0066 (−0.0065 to 0.0197) | 0.1212 | 0.32 | 0 |
| D-dimers§ | 30 | 0.0027 (0.0004 to 0.0051) | 0.1183 | 0.02 | 14 |
| Proportion of patients receiving anticoagulation | 38 | 0.0016 (−0.0013 to 0.0044) | 0.0311 | 0.29 | 0 |
| Proportion of men | 40 | 0.0042 (−0.0002 to 0.0087) | −0.0833 | 0.06 | 5 |

R² estimates the amount of heterogeneity accounted for by the moderators. *Beta signification: prevalence increase or decrease for the augmentation of one unit of the variable tested. †Intercept signification: rate of venous thromboembolism for a variable with null value. ‡Per increase of 100 patients. §Per increase of 100 µg/L.
activated partial thromboplastin time,\textsuperscript{15} invasive mechanical ventilation,\textsuperscript{14} as well as high levels of plasma factor VIII activity,\textsuperscript{60} and factor Willebrand antigen.\textsuperscript{60} Interestingly, the exact mechanisms resulting in PE in severe COVID-19 have been questioned. Indeed, disseminated intravascular coagulation, a condition characterised by the generation of microthrombi in different organs, including the pulmonary circulation,\textsuperscript{119} has been frequently reported in non-survivors of COVID-19.\textsuperscript{120-122} Pulmonary microthrombi were also reported at lung dissection from critically ill patients with COVID-19.\textsuperscript{2} This is in line with the immunothrombosis model, which highlights the bidirectional relationship between the immune system and thrombin generation during severe infection\textsuperscript{123} and the pathogenesis of acute respiratory distress syndrome.\textsuperscript{124} The mechanisms involved in COVID-19-related thrombosis nonetheless remain unclear and may include, in addition to classical pulmonary thromboemboli, intravascular coagulopathy,\textsuperscript{118} 125 126 systemic and endothelial inflammation promoting factor Willebrand antigen, fibrinogen and factor VIII activity,\textsuperscript{51} immune-mediated damage by antiphospholipid antibodies\textsuperscript{51} 127 and hypoxaemia-induced vascular occlusion.\textsuperscript{51} 128 129

Importantly, a recent study suggested that the pre-emptive anticoagulation with heparin was associated with decreased mortality among patients with significant sepsis-induced coagulopathy or markedly elevated D-dimer levels.\textsuperscript{129} Whether these beneficial effects were related to non-anticoagulant properties of heparin, including its anti-inflammatory, antiviral\textsuperscript{130} and protective effects on the pulmonary endothelium, remained unknown.\textsuperscript{131} As recognised by the authors, however, this retrospective study was subjected to bias, and its results were not replicated in subsequent studies, suggesting that conventional thromboprophylactic prophylaxis or therapeutic anticoagulant had limited effects on VTE risk in patients with severe COVID-19.\textsuperscript{132} 133 Moreover, while the prevalence of VTE and ATE appears substantial, a previous series of 113 patients with severe sepsis and septic shock hospitalised in the ICU reported a VTE prevalence of 37.2%.\textsuperscript{133} Consistently, the prevalence of VTE for patients receiving thromboprophylaxis while hospitalised on general wards for other medical illnesses,\textsuperscript{134} 135 as well as the ATE risk of patients with community-acquired pneumonia,\textsuperscript{136} 137 was somewhat similar to that observed in patients with COVID-19 in the present meta-analysis. In the context of the increased risk of bleeding\textsuperscript{138} and previous negative trials of endogenous anticoagulants in sepsis,\textsuperscript{139} these indirect comparisons question the recent recommendations for an early therapeutic anticoagulation for patients with sepsis-related coagulopathy in the context of severe COVID-19.\textsuperscript{8} 9 As a result, the efficacy, dosage and characteristics of patients most suitable for high-prophylactic doses or systemic anticoagulation remain to be demonstrated in prospective controlled studies before they become standard of care in patients who may also be at increased bleeding risk.\textsuperscript{137} 48 50 85 99

The present study has some limitations. First, we only partially explained the high level of heterogeneity across studies for VTE. In other words, the estimates of VTE rate cannot be used to compute the individualised risk of a given patient admitted in the general ward or the ICU. Second, the prevalence may have been overestimated due to design, sampling, measurement, confounder and information biases. For example, follow-up duration was limited to the first few weeks following ICU admission, which is associated with the highest thrombotic risk.\textsuperscript{34} 53 A high number of CT scans were also likely performed for COVID-19, with PE events being potentially observed as an incidental findings only. The increasing awareness about the association between COVID-19 and VTE–ATE may have also lowered the physicians’ threshold for ordering imaging studies, especially in case of suspected PE in patients in the ICU. Although sensitivity analyses excluding the two studies\textsuperscript{17} 64 reporting potential PE were not significantly associated with venous thromboembolism when added to the model. As an example, the prevalence of venous thromboembolism in a cohort using systematic screening and including 30% of patients in the ICU is estimated at 0.0051+0.1423+0.0020×30=0.2374 (23.7%).

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|l|l|}
\hline
Beta* & 95\% CI & Intercept & P value \\
\hline
Proportion of patients in ICU (%) & 0.0020 & 0.0012 to 0.0028 & 0.0351 & <0.0001 \\
Systematic screening (yes/no) & 0.1423 & 0.0590 to 0.2256 & 0.0351 & 0.0008 \\
\hline
\end{tabular}
\caption{Table 3 Mutivariable analysis of 47 studies reporting prevalence of venous thromboembolism.}
\end{table}

\begin{flushright}
Number of patients (47 studies, p=0.57) and D-dimer level (28 studies, p=0.26) were not significantly associated with venous thromboembolism when added to the model.
\end{flushright}

*Beta signification: prevalence increase or decrease for the augmentation of one unit of the variable tested.

Intercept signification: rate of venous thromboembolism for all variables with null value.

ICU, intensive care unit.
Critical care

Figure 4

Forest plot showing the pooled, weighted frequency of patients with ATE. Others included visceral and limb ischaemia. ACS, acute coronary syndrome; ATE, arterial thromboembolic event; MI, myocardial infarction.

| Study | Events Total | Events per 100 observations | Events 95% CI |
|-------|--------------|-----------------------------|--------------|
| ATE = All events | | | |
| Al-Samkari et al | 11 400 | 2.5 [1.4; 4.5] |
| Betoule et al | 3 76 | 3.9 [0.8; 11.1] |
| Blandeghini et al | 365 3334 | 10.9 [9.8; 12.1] |
| Cantadori et al | 14 1419 | 1.0 [0.5; 1.6] |
| Fraitak et al | 8 92 | 8.7 [3.8; 16.4] |
| Hand et al | 13 901 | 1.4 [0.8; 2.4] |
| Heidt et al | 4 150 | 2.7 [0.7; 8.7] |
| Khik et al | 3 184 | 1.6 [0.3; 4.7] |
| Incardio et al | 3 99 | 3.0 [0.6; 6.9] |
| Lodigiani et al | 13 314 | 4.1 [2.2; 7.3] |
| Pispal et al | 4 398 | 1.0 [0.3; 2.6] |
| Rauch et al | 3 243 | 1.2 [0.3; 3.6] |
| Shah et al | 25 187 | 13.4 [6.8; 19.1] |
| Thomas et al | 2 63 | 3.2 [0.4; 11.0] |
| Voiti et al | 17 93 | 18.3 [11.0; 27.4] |
| Zemmer et al | 2 100 | 2.0 [0.2; 7.0] |
| Zhang et al | 1 28 | 3.6 [0.1; 11.3] |
| Fixed effect model | 6249 | 5.0 [4.5; 5.4] |
| Random effects model | 4.0 [2.0; 8.5] |

Heterogeneity: F = 90%, F = 80%, p = 0.01

ATE = ACS/MI

Al-Samkari et al | 10 400 | 2.5 [1.2; 4.5] |
| Betoule et al | 0 76 | 0.0 [0.0; 4.7] |
| Blandeghini et al | 268 3334 | 8.9 [5.0; 13.0] |
| Beut et al | 0 75 | 0.0 [0.0; 4.8] |
| Cantadori et al | 3 1419 | 0.2 [0.0; 0.5] |
| Fraitak et al | 1 92 | 1.1 [0.5; 13.0] |
| Heidt et al | 0 150 | 0.0 [0.0; 2.4] |
| Khik et al | 0 184 | 0.0 [0.0; 2.0] |
| Lodigiani et al | 4 314 | 1.3 [0.3; 3.2] |
| Studer-Kopp et al | 11 1226 | 0.9 [0.5; 1.6] |
| Rauch et al | 1 243 | 0.4 [0.1; 2.3] |
| Shah et al | 5 187 | 2.7 [0.9; 6.1] |
| Thomas et al | 2 63 | 3.2 [0.4; 11.0] |
| Voiti et al | 3 93 | 3.2 [0.7; 9.1] |
| Zemmer et al | 1 73 | 1.4 [0.6; 1.7] |
| Zhang et al | 1 28 | 3.6 [0.1; 16.3] |
| Fixed effect model | 7929 | 3.0 [2.7; 3.4] |
| Random effects model | 1.1 [0.2; 3.6] |

Heterogeneity: F = 90%, F = 80%, p = 0.01

ATE = Ischemic stroke

Arne et al | 64 9256 | 0.7 [0.5; 0.9] |
| Betoule et al | 2 75 | 2.6 [0.9; 4.9] |
| Beut et al | 2 75 | 2.7 [0.9; 3.3] |
| Blandeghini et al | 54 3334 | 1.6 [1.2; 2.1] |
| Cantadori et al | 6 1419 | 0.4 [0.2; 0.9] |
| Du et al | 3 164 | 1.9 [0.4; 5.3] |
| Eeftinck et al | 5 1236 | 0.0 [0.0; 0.1] |
| Focht et al | 6 96 | 7.0 [2.6; 14.6] |
| Friedmann et al | 3 99 | 3.0 [0.6; 4.8] |
| Fraitak et al | 2 92 | 2.2 [0.3; 7.4] |
| Hand et al | 11 901 | 1.2 [0.6; 1.7] |
| Heidt et al | 2 150 | 1.3 [0.2; 4.7] |
| Khik et al | 5 184 | 2.7 [1.0; 6.2] |
| Lodigiani et al | 9 314 | 2.9 [1.3; 6.6] |
| Li et al | 10 219 | 4.6 [2.2; 9.2] |
| Mao et al | 6 214 | 2.8 [1.6; 4.0] |
| Politi et al | 3 99 | 0.8 [0.2; 2.7] |
| Rauch et al | 2 243 | 0.8 [0.1; 2.9] |
| Shah et al | 19 187 | 4.3 [1.9; 9.3] |
| Shaltouti et al | 123 6356 | 1.9 [1.6; 2.3] |
| Steffann et al | 4 165 | 2.4 [0.7; 6.1] |
| Thomas et al | 0 63 | 0.0 [0.0; 5.7] |
| Zemmer et al | 1 73 | 1.4 [0.0; 7.4] |
| Zhang et al | 0 28 | 0.0 [0.0; 12.3] |
| Naghi et al | 32 3556 | 0.9 [0.6; 1.3] |
| Voiti et al | 3 93 | 3.2 [0.7; 9.1] |
| Zemmer et al | 1 100 | 1.0 [0.0; 5.4] |
| Fixed effect model | 40997 | 0.7 [0.6; 0.7] |
| Random effects model | 1.6 [1.0; 2.2] |

Heterogeneity: F = 90%, F = 80%, p = 0.01

ATE = Others

Al-Samkari et al | 1 400 | 0.2 [0.0; 1.4] |
| Betoule et al | 1 76 | 1.3 [0.0; 7.1] |
| Beut et al | 0 75 | 0.0 [0.0; 4.8] |
| Blandeghini et al | 33 3334 | 1.0 [0.7; 1.4] |
| Cantadori et al | 3 1419 | 0.2 [0.0; 0.6] |
| Eeftinck et al | 49 1236 | 0.4 [0.3; 0.5] |
| Fraitak et al | 5 92 | 0.4 [1.8; 12.3] |
| Hand et al | 2 901 | 0.2 [0.0; 0.8] |
| Heidt et al | 2 150 | 1.3 [0.2; 4.7] |
| Khik et al | 2 184 | 1.1 [0.1; 3.9] |
| Lodigiani et al | 0 314 | 0.0 [0.0; 1.2] |
| Shah et al | 12 187 | 0.4 [3.4; 10.9] |
| Thomas et al | 0 63 | 0.0 [0.0; 5.7] |
| Voiti et al | 11 93 | 11.8 [6.1; 20.0] |
| Zemmer et al | 2 73 | 2.7 [0.3; 3.9] |
| Zemmer et al | 1 100 | 1.0 [0.0; 5.4] |
| Zhang et al | 0 25 | 0.0 [0.0; 12.5] |
| Fixed effect model | 20139 | 0.5 [0.4; 0.6] |
| Random effects model | 0.9 [0.5; 1.5] |

Heterogeneity: F = 90%, F = 80%, p = 0.01

Figure 4 - Forest plot showing the pooled, weighted frequency of patients with ATE. Others included visceral and limb ischaemia. ACS, acute coronary syndrome; ATE, arterial thromboembolic event; MI, myocardial infarction.
In conclusion, patients admitted in the ICU for COVID-19 appear to have a high risk of VTE. Physicians should therefore have a high index of suspicion, especially in patients with some dissociation between relatively well-preserved lung mechanics and significant hypoxaemia. However, the optimal management for VTE prevention and treatment remains to be defined. Moreover, further studies are also needed to determine the specific effects of COVID-19 on the risk of ATE and VTE, especially in less severe forms of the disease.

Author affiliations
1 Department of Intensive Care Unit, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
2 Department of Internal and Vascular Medicine, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
3 Équipe Evaluation et Modélisation des Effets Thérapeutiques, UMR - CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive, Claude Bernard University Lyon 1, Villeurbanne, France
4 Service de Médecine Vasculaire et Thérapeutique, CHU de Saint-Etienne, Saint-Etienne, France
5 Université Jean-Monnet, UMR 1059, SAINBIOSE: INSERM CIC 1408, Saint-Etienne, France
6 Service d’accueil des urgences, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
7 Groupe d’Étude Multidisciplinaire des Maladies Thrombotiques, Hospices Civils de Lyon, Lyon, France
8 Unité d’Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France
9 Department of Internal Medicine, CHU de Clermont-Ferrand, Clermont-Ferrand, France
10 Pulmonary Hypertension Research Group, Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Québec, Canada

Correction notice This article has been corrected since it was published Online First. Affiliations for LB have been updated.

Twitter Laurent Bertolotti @LaurentBertolte1

Contributors BKT, SM, SP and J-CL designed the study. BKT and J-CL performed study selection. BKT, J-CL and SM extracted data from selected studies. J-CL and SM performed the statistical analysis. SM, BKT, J-CL, AF, YD and SP analysed the data. This first draft was written by BKT, SP and J-CL. J-CL is the guarantor. All authors contributed to the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests LB reports grants and personal fees from Sanofi; grants, personal fees and non-financial support from Leo-Pharma; personal fees and non-financial support from Aspen; grants, personal fees and non-financial support from BMS/Pfizer; grants, personal fees and non-financial support from Bayer during the conduct of the study. GC has received grants from Bayer and BMS/Pfizer. YD has received grants/research support from Bayer, Baxter, Baxalta, Nexo Nordisk, CSL Behring, LFB, Pfizer, LeoPharma, Octapharma and Stago; and an educational grant from Takeda and honoraria from Bayer, Baxter, Novo Nordisk, CSL Behring, Sobi and Octapharma. SP reports grants from Actelion, AstraZeneca and Resverlogix outside the submitted work.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Data have been provided in the figures and tables.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise stated for the duration of the covid-19 pandemic or until otherwise required by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

REFERENCES
1. McGregor D, O’Donnell JS, Shariat F, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020;2:e437–45.
2. Lippi G, Favaloro EJ, D-Dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020;120:876–8.
3. Danzi GB, Loffi M, Galeazzi G, et al. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J 2020;41:41.
4. Cattaneo M, Bertiniato EM, Birocchi S, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost 2020;120:1230–2.
5. Litjós JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020;18:1743–6.
6. Klok FA, Kruip MHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.
7. Thomas W, Varley J, Johnston A, et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res 2020;191:76–7.
8. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023–6.
9. Bickel B, MadHAVN MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75:2950–73.
10. Cumpston M, Lit T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019;10:CD001422.
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
12. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–6.
13. Barendregt JJ, Doi SA, Lee YY, et al. Meta-analysis of prevalence. J Epidemiol Community Health 2013;67:974–8.
14. Grillo F, Behr J, Calame P, et al. Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiology 2020;296:E186–8.
15. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18:1421–4.
16. Gagnier JJ, Morgenstern H, Altman DG, et al. Consolidated-Best Practices for investigating clinical heterogeneity in systematic reviews. BMC Med Res Methodol 2013;13:106.
17. Al-Samkani H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136:489–500.
18. Bilaloglu S, Apyanypanghongs Y, Jones S, et al. Thrombosis in hospitalized patients with COVID-19 in a new York City health system. JAMA 2020;324:799.
19. Artifoni M, Daric G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis 2020;50:211–6.
20. Aversa M, Benvenuto L, Anderson M, et al. COVID-19 in lung transplant recipients: a single center case series from New York City. Am J Transplant 2020;20:3072–80.
21. Choi JJ, Wehmeier GT, LI HA, et al. D-Dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19. Thromb Res 2020;196:318–21.
22. Demelo-Rodriguez P, Cervilla-Muñoz E, Ordieres-Ortega L, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 2020;192:23–6.
23. Dubois-Silva Álvaro, Barbagalatá-Lópeç C, Mena Álvaro, et al. Pulmonary embolism and screening for concomitant proximal deep vein thrombosis in noncritically ill hospitalized patients with coronavirus disease 2019. Intern Emerg Med 2020;15:865–70.
24. Dumantepe M, Aydin S, Yildiz E. Withheld: subsegmental thrombus in COVID-19 pneumonia: Immuno-Thrombosis or pulmonary embolism? data analysis of hospitalized patients with coronavirus disease. Heart Lung and Circulation 2020;39:30435–2.
25. Galeano-Valle F, Oblitas CM, Ferreiro-Alves MM, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 2020;192:113–5.
26. Giorgi-Pierfranceschi M, Paolotti O, Pan A. Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study. Intern Emerg Med 2020.
27. Hanif A, Khan S, Mantri N, et al. Thrombotic complications and anticoagulation in COVID-19 pneumonia: a new York City hospital experience. Ann Hematol 2020;99:2323–8.
Longchamp A, Longchamp J, Manzočić-Bessoon S, et al. Venous thromboembolism in critically ill patients with COVID-19: results of a screening study for deep vein thrombosis. Res Pract Thromb Haemost 2020;4:842–7.

Longhiyan T, Racca F, Zanca C, et al. Venous thromboembolism in critically ill patients affected by ARDS related to COVID-19 in Northern-West Italy. Eur Rev Med Pharmacol Sci 2020;24:9154–60.

Maatman TK, Jalali F, Feizpour C, et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med 2020;48:783–90.

Pavoni V, Gianesello L, Pazzi M, et al. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: a call to action. Thromb Res 2020;196:313–7.

Peyssy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020;142:184–6.

Shah A, Donovan K, McHugh A, et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. Crit Care 2020;24:561.

Stefely JA, Christensen BB, Gogakos T, et al. Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism. Am J Hematol 2020;95:1522–30.

Taccorne FS, Guevornik PA, Puleso L, et al. Higher intensity thromboprophylaxis regimens and pulmonary embolism in critically ill coronavirus disease 2019 patients. Crit Care Med 2020;48:e1087–90.

Tavazzi G, Civardi L, Carave L, et al. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. Intensive Care Med 2020;46:1121–3.

Violf F, Ceccegai L, Gangan L, et al. Hyperalbuminemia, coagulopathy, and vascular disease in COVID-19. Cir Res 2020;127:400–1.

Zangrillo A, Beretta L, Scardoglio LG. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resusc 2020; [Epub ahead of print: 23 Apr 2020].

Zerrmatten MG, Pantet O, Gomez F, et al. Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19. Thromb Res 2020;196:222–6.

Piagnerelli M, Cauchie P, Vancunte M, et al. Thromboprophylaxis in critically ill coronavirus disease 2019 patients. Crit Care Explo 2020;2:e0177.

Alharthy A, Faqidi F, Memish ZA, et al. Lung injury in COVID-19: An emerging hypothesis. ACS Chem Neurosci 2020;11:2156–8.

Bleys C, Huytte P, Abou-Arab O, et al. Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis. Br J Anaesth 2020;125:e260–2.

Mueller-Peltzer K, Kraus T, Benndorf M, et al. Pulmonary artery thrombi are co-located with opacifications in SARS-CoV-2 induced ARDS. Respir Med 2020;172:106135.

Soumagne T, Lascarrou J-B, Hraiech S, et al. Factors associated with pulmonary embolism among coronavirus disease 2019 acute respiratory distress syndrome: a multicenter study among 375 patients. Crit Care Explo 2020;2:e0166.

Wright MB, Kelly PA, Gonzalez E, et al. Pulmonary embolism in hospitalised patients with COVID-19. Thromb Res 2020;195:95–9.

Alonso-Fernández A, Toledo-Pons N, Cosio BG, et al. Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: a prospective study. PloS One 2020;15:e0238216.

Saeed MT, Alhaj J, Alsaif A, et al. Pulmonary thromboembolism in COVID-19 pneumonia patients with severe COVID-19: a multicenter study and meta-analysis. Eur J Neurol 2021;28:238–47.

Stoneham SM, Milne KM, Nuttall E, et al. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med 2020;20:e67–81.

Trimaille A, Curtiaud A, Marchandot B, et al. Venous thromboembolism in critically ill patients with COVID-19 infection. Thromb Res 2020;193:166–9.

Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31:894–901.

Aleva FE, van Mourik L, Broeders MEAC, et al. COVID-19 in critically ill patients in a tertiary critical care unit in the United Kingdom. Dan Med J 2020;60:9.

Behe R, Kusadasi N, Sikma M, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Ann Vasc Surg 2020;76:43–9.

Benito N, Filia L, Mateu I, et al. Pulmonary thrombosis or embolism in a large cohort of hospitalized patients with Covid-19. Front Med 2020;7:557.

Bompad F, Monnier H, Saab J, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J 2020;56:2001365. doi:10.1183/13993003.01365-2020.

Campopiano C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 2020;76:43–5.

Equiluz O, Rodríguez Sevilla JJ, Rodríguez Chiaradía DA. Ct imaging of pulmonary thromboembolism in COVID-19 patients. J Thorac Imaging 2020;35:W45–9.

Espallargas I, Rodríguez Sevilla U, Rodríguez Chiradita DA. Ct imaging of pulmonary embolism in patients with COVID-19 pneumonia: a retrospective analysis. Eur Radiol 2020;39:1–8.

Fauvel C, Weizman O, Trimaille A, et al. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J 2020;41:3058–68.

Frerup Y, Drogem Y, Miró Òscar, et al. Association between pulmonary embolism and COVID-19 in emergency department patients undergoing computed tomography pulmonary angiogram: the PEPCOV international retrospective study. Acad Emerg Med 2020;27:811–20.

Gervais A, Bouzad C, Peroue E, et al. Acute pulmonary embolism in non-hospitalized COVID-19 patients referred to CtpA by emergency department. Eur Radiol 2020;30:6170–7.

Larsen K, Coolem-Alou M, Nasse L, et al. Detection of pulmonary embolism in returning travelers with hypoxic pneumonia due to COVID-19 in reunion island. Am J Trop Med Hyg 2020;103:844–6.

Lendorf ME, Boisen MK, Kristensen PL, et al. Characteristics and early outcomes of patients hospitalised for COVID-19 in North Zealand, Denmark. Dan Med J 2020;67:a06040248.
Critical care

84 Mestre-Gómez B, Lorente-Ramos RM, Rogado J, et al. Incidence of pulmonary embolism in non-critically ill COVID-19 patients, predicting factors for a challenging diagnosis. J Thromb Thrombolysis 2021;51:40–6.

85 Moll M, Zon RL, Sylvester KW, et al. Vte in ICU patients with COVID-19. Chest 2020;158:2130–5.

86 Montarini L, Nortass M, Botti P, et al. Pulmonary thromboembolism in hospitalised COVID-19 patients at moderate to high risk by Wells score: a report from Lombardy, Italy. Br J Radiol 2020;93:20200407.

87 Mouhat B, Besutti M, Boullier K, et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J 2020;56:200181.

88 Zhang P, Qu I, Tu J. Applicability of bedside ultrasonography for the diagnosis of deep venous thrombosis in patients with COVID-19 and treatment with low molecular weight heparin. J Clin Ultrasound 2020. [Epub ahead of print: 05 Aug 2020].

89 Nahum J, Morichau-Beauchant T, Daviau F, et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open 2020;2:e2001478.

90 Ren B, Yan F, Deng Z, et al. Extremely high incidence of lower extremity deep venous thrombosis in 46 patients with severe COVID-19 in Wuhan. Circulation 2020;142:181–3.

91 Torres-Machorro A, Anguiano-Alvarez VM, Grimaldo-Gómez FA, et al. Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity. Thromb Res 2020;196:268–71.

92 Trigoni RA, Holt DB, Yuan R, et al. Incidence of venous thromboembolism in critically ill COVID-19 patients receiving prophylactic anticoagulation. Crit Care Med 2020;48:e805–8.

93 Voicu S, Bonnin P, Stépianian A, et al. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients. J Am Coll Cardiol 2020;76:480–2.

94 Yu B, Li X, Chen J, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis 2020;50:548–57.

95 Beigel JH, Tomashke KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020;383:1813–26.

96 Bozzani A, Tavazzi G, Arici V, et al. Acute deep vein thrombosis in COVID-19 hospitalized patients. risk factors and clinical outcomes. Phlebology 2020;2020:268355520998598.

97 Jimenez-Guiñi X, Huici-Sanchez M, Romera-Villegas A, et al. Deep vein thrombosis in non-critically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in non-intensive care unit patients. J Vasc Surg Venous Lymph Disord 2020;3:30466–2.

98 Xing C, Li Q, Du H, et al. Lung ultrasound findings in patients with COVID-19 pneumonia. Crit Care 2020;24.

99 Léonard-Lorant J, Delabranche X, Severa F, et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to D-dimer levels. Radiology 2020;296:189–91.

100 Santoliquido A, Portifia A, Nesca I, et al. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J Thromb Haemost 2020;18:2358–63.

101 Betoule A, Martinet C, Gasparrini G, et al. Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients. J Thromb Thrombolysis 2020;50:302–4.

102 Cantador E, Núñez A, Sobrino P, et al. Incidence and consequences of systemic arterial thromboembolic events in COVID-19 patients. J Thromb Thrombolysis 2020;50:543–7.

103 Studart-Neto A, Guedes BF, Tuma Ridel-E, et al. Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital. Arq Neuropsiquiatr 2020;78:494–500.

104 Annie F, Bates MC, Nanjundappa A, et al. Prevalence and outcomes of acute ischemic stroke among patients ≥50 years of age with laboratory confirmed COVID-19 infection. Am J Cardiol 2020;130:169–70.

105 Du H, Pan X, Liu N, et al. The effect of vascular risk factor burden on the severity of COVID-19 illness. A retrospective cohort study. Respir Res 2020;21:241.

106 Etkin Y, Conway AM, Silpe J, et al. Acute arterial thromboembolism in patients with COVID-19 in the New York City area. Ann Vasc Surg 2021;70:290–4.

107 Fan S, Xiao M, Han F, et al. Neurological manifestations in critically ill patients with COVID-19: a retrospective study. Front Neurol 2020;11:806.

108 Fridman S, Bres Bulruch M, Jiménez-Ruíz A, et al. Stroke risk, phenotypes, and death in COVID. A systemic review and newly reported cases. Neurology 2020;95:e3373–85.

109 Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neuro 2020;5:279–84.

110 Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurology 2020;77:683.

111 Shahjouei S, Naderi S, Li L, et al. Risk of stroke in hospitalized SARS-CoV-2 infected patients: a multinational study. Ebiomedicine 2020;59:102539.